Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Has “Critical Mass” In R&D And Sales; Faces Tough 2004

Executive Summary

Bristol-Myers Squibb believes it has the "critical mass" in R&D and sales to continue as a stand-alone company, CEO Peter Dolan said Jan. 29 during the company's year end earnings call

You may also be interested in...



Therapeutic Area Focus Could Pay Off In Biomarker Discovery, Bristol VP Says

Having an R&D focus on targeted therapeutic areas could be beneficial in terms of developing biomarkers, according to a Bristol-Myers Squibb exec

Therapeutic Area Focus Could Pay Off In Biomarker Discovery, Bristol VP Says

Having an R&D focus on targeted therapeutic areas could be beneficial in terms of developing biomarkers, according to a Bristol-Myers Squibb exec

Bristol Late-Stage Pipeline Reflects Success Of In-House Development

Bristol-Myers Squibb's late-stage pipeline will include 80% internally developed agents, with three of those compounds moving into Phase III

Related Content

UsernamePublicRestriction

Register

OM016808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel